gennova.bio Open in urlscan Pro
199.79.62.78  Public Scan

Form analysis
2 forms found in the DOM

GET https://gennova.bio/

<form class="searchform menusearchform" method="get" action="https://gennova.bio/">
  <a class="search_btn"><i class="icon-search-6"></i></a>
  <div class="popup_form"><input type="text" class="form-control" name="s" placeholder="Search"></div>
</form>

GET https://gennova.bio/

<form class="searchform menusearchform" method="get" action="https://gennova.bio/">
  <a class="search_btn"><i class="icon-search-6"></i></a>
  <div class="popup_form"><input type="text" class="form-control" name="s" placeholder="Search"></div>
</form>

Text Content

 * Home›
   * Home ‹ Back
   * Contact Us
     
 * About Us›
   * About Us ‹ Back
   * Company Profile
   * Our Values
   * Board of Directors
   * Our Strengths
   * PDL
   * Our Collaborations
     
 * Media›
   * Media ‹ Back
   * News Coverage
   * Gallery
   * Employee Moments
     
 * Products›
   * Products ‹ Back
   * Elaxim®
   * TENECTASE®
   * Vintor®
   * Xgrast®300
   * PEGEX®
   * EMGRAST®-M
   * Hamsyl®
   * GEMCOVAC®-19
     
 * Publications
 * Abhyudaya
 * Global Health Initiative›
   * Global Health Initiative ‹ Back
   * PHT
   * Stroke
     
 * 


 * Home›
   * Home ‹ Back
   * Contact Us
     
 * About Us›
   * About Us ‹ Back
   * Company Profile
   * Our Values
   * Board of Directors
   * Our Strengths
   * PDL
   * Our Collaborations
     
 * Media›
   * Media ‹ Back
   * News Coverage
   * Gallery
   * Employee Moments
     
 * Products›
   * Products ‹ Back
   * Elaxim®
   * TENECTASE®
   * Vintor®
   * Xgrast®300
   * PEGEX®
   * EMGRAST®-M
   * Hamsyl®
   * GEMCOVAC®-19
     
 * Publications
 * Abhyudaya
 * Global Health Initiative›
   * Global Health Initiative ‹ Back
   * PHT
   * Stroke
     
 * 

   
 * Cardiovascular
   ST-Elevation Myocardial Infarction (STEMI) occurs due to occlusion in one or
   more of
   
   the coronary arteries supplying blood to the heart. Reperfusion therapy with
   single bolus
   tenecteplase (Elaxim™) in a timely manner improves blood flow in the infarct
   related coronary
   artery and reduces mortality. Elaxim™, a 3rd generation thrombolytic has
   impacted more than
   200,000 lives in the last decade. This cost effective innovation has
   revolutionized the STEMI
   patient management in India and other emerging markets.
   
 * Neurology
   Acute Ischemic Stroke (AIS) is a medical emergency. It occurs due to arterial
   occlusion and is
   
   associated with very high morbidity and mortality. Intravenous thrombolysis
   with tenecteplase
   (Tenectase®), a 3rd generation agent, approved by Drug Controller General of
   India improves
   outcomes in patients with AIS. Tenectase® is safe, easy to administer and
   cost effective,
   making it an attractive alternative for reperfusion therapy in stroke.
   
 * Nephrology
   Vintor 2000, 3000, 4000, 6000, 10000, 20000 and 40000
   
   Erythropoietin, used for patients suffering with Chronic Renal Failure, has
   been saving lives
   of millions of patients since its launch in India in 2007
   
 * Oncology
   G-CSF and GM-CSF from Gennova are supplementing multiple cancer treatment for
   over
   
   a decade now. PEGylated long lasting version of G-CSF provides the same
   medical benefit
   but with a significantly reduced dose regimen. Our PEGylated asparaginase has
   been saving
   lives of hundreds of children suffering from ALL Compared to L-asparaginase,
   PEGasparagase
   has lower immunogenicity and reduced dosing.
   
 * DBT-Biotech Award Ceremony
   Dr. Sanjay Singh receives the “DBT-Biotech Product, Process Development and
   
   Commercialization award 2019 (under Organization category)” for the
   development of
   Tenectase, a 3rd generation thrombolytic glycoprotein for acute ischemic
   stroke (AIS) from
   Honourable Minister of Railways and Minister of Commerce and Industry – Shri
   Piyush Goyal.
   









TRANSFORMING HEALTHCARE




ONE OF OUR GREATEST ASSETS IS OUR APPRECIATION AND UNDERSTANDING OF THE
COMPLEXITY OF A PROBLEM AND DEDICATED FOCUS TO DEVELOP A LONG LASTING SOLUTION
INSTEAD OF LOOKING FOR A QUICK FIX. WE REALIZED EARLY ON THAT WE WILL NOT BE
ABLE TO DEVELOP, DELIVER AND SURVIVE IN THE COMPETITIVE MARKET OF BIOTECHNOLOGY
IF WE DO NOT INNOVATE ACROSS ALL THE REQUIRED SCIENTIFIC PLATFORMS. THIS IS WHAT
SEPARATES US FROM THE REST OF THE TRADITIONAL BIOTECHNOLOGY COMPANIES INTERESTED
IN MAKING BIOSIMILAR.





COMPANY HIGHLIGHTS



Gene to Market

 * 7 Commercialized Bio-therapeutics
 * 6 biosimilars – 1 of them in top 20 best selling drugs
 * 1 novel product

Platform Technology

 * Next generation, bio-manufacturing platform that reduces COGs
 * Small facility footprint leads to significant reduction in OPEX
 * Readily scalable & robust technology



Potential

 * Value creation through cutting edge science
 * AI guided innovation in Bio-manufacturing, disease Diagnosis & Treatment
 * Value appropriation through Intellectual Properties

Team

 * A strong leadership team, experienced in successful global collaboration and
   execution

Finance

 * A profit making, debt free, growing firm with an established track record of
   about a decade and a half

Pipeline

 * Biosimilars
 * Vaccines
 * Novel bio-therapeutics





PRODUCT MILESTONES







INFRASTRUCTURE



Other than our marketing strategies our investment in the technological
development of the infrastructure gives us an edge over others. We have
experience and expertise that allows us to develop innovative and cost effective
products because of the cutting edge technology backed by research.


GLOBAL COLLABORATIONS



“Many factors play an important role in the process of Transforming Healthcare,
and one of the most important is that we cannot innovate in isolation. We have
to have collaborations.”

– Dr. Sanjay Singh, CEO, Gennova Biopharmaceuticals Ltd.




BENCH TO BEDSIDE



We have a team of experienced and capable scientists and technocrats who have
developed capabilities across scientific, manufacturing, regulatory, clinical
and business arenas that have made it successful in the Indian market.
The experience and capabilities will facilitate the expansion of business in the
global market for our current and pipeline products.







ABOUT GENNOVA

Board of Directors
Global Health Initiative
Corporate Governance
Internships
Careers
Press Kit
Contact Us


PRODUCTS

Elaxim®
TENECTASE®
Vintor®
Xgrast®300

PEGEX®
Emgrast®-M
Hamsyl®
GEMCOVAC®-19

©2006-2023 Gennova Biopharmaceuticals Limited. All rights reserved.